<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1425">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04346147</url>
  </required_header>
  <id_info>
    <org_study_id>24032020</org_study_id>
    <nct_id>NCT04346147</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19</brief_title>
  <acronym>Covid-19HUF</acronym>
  <official_title>Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Hydroxychloroquine Together With Baricitinib, Imatinib or Early Lopinavir / Ritonavir in Patients With SARS Cov2 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario de Fuenlabrada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro Nacional de Investigaciones Oncologicas CARLOS III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario de Fuenlabrada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In absence of vaccine and medications specifically designed to treat SARS-CoV-2 disease,
      identifying treatment options is critical at this time to control the disease outbreak.

      For this, we have designed a phase II trial of efficacy and safety with 3 branches of
      different combinations of treatment to identify which is the best early treatment option for
      patients with pneumonia due to SARS-CoV-2 (Covid-19) Identifying treatment options as early
      as possible is critical to the SARS-CoV-2 outbreak response. Currently, there is no approved
      vaccine for the disease and the treatments being used are not specifically designed for the
      SARS-CoV-2 virus, but are different groups of drugs used for other pathologies with
      mechanisms of action that justify their use because they inhibit entry of the virus into
      virus cells or proteases.

      The study aims to compare lopinavir / ritonavir (200 /50), imatinib 400mg, baricitinib 4mg,
      in combination with hydroxychloroquine 200mg, administered for 7 days in the setting of
      SARS-CoV-2 pneumonia treatment.

      Patients who meet inclusion criteria and do not have any exclusion criteria will be
      randomized to receive open treatment 1:1:1
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Identifying treatment options is critical to the SARS-CoV-2 outbreak response. Currently
      there is no vaccine and treatments used are not specifically designed for this virus; They
      are drugs used for other pathologies. We have identified possible drugs with a known safety
      profile, selected the most promising ones and designed 3 combinations to select the one with
      the best results in clinical improvement of pneumonia due to Covid-19.

      -Virus entry inhibitors: broad spectrum antivirals (antimalarials). They block viral
      infection by increasing endosomal pH necessary for virus / cell fusion, as well as
      interfering with glycosylation of cellular SARS-CoV receptors. It also has immunomodulatory
      activity, which can enhance antiviral effect. Hydroxychloroquine more powerful than
      chloroquine.

      Baricitinib, Janus kinase inhibitor, showing high affinity for AAK1. Disruption of AAK1 (one
      of the known regulators of viral endocytosis) could block passage of SARS-CoV-2 to cells and
      also the intracellular assembly of virus particles. Furthermore, it has the capacity to bind
      cyclin G-associated kinase, another regulator of endocytosis. You can limit systemic
      inflammatory response and cytokine production by inhibiting the JAK-STAT32 pathway.

      Imatinib; Antitumor agent inhibitory activity of some tirsin kinases (TK), especially fusion
      oncoprotein BCR-ABL1, c-kit and native kinase ABL1. It has shown antiviral properties in
      early stages of infection against SARS-CoV and MERS-CoV, phylogenetically related to
      SARS-CoV2. In addition, it has been linked to reduced inflammation and improved endothelial
      barrier and pulmonary edema.

      -Protease inhibitors: lopinavir / ritonavir (HIV treatment); expected interactions with
      SARS-CoV-2 proteases; The therapeutic effect of ritonavir and lopinavir could be mainly due
      to its inhibitory effect on coronavirus endopeptidase C30.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to clinical improvement</measure>
    <time_frame>baseline to day 14</time_frame>
    <description>time from inclusion to improvement by 2 points on the &quot;seven-category ordinal scale&quot; or high, whichever comes first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of treatments</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>number of serious adverse effects and premature discontinuation of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of treatments</measure>
    <time_frame>during treatment and up to 30 days after the last treatment dose</time_frame>
    <description>Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarkers and genetic markers of susceptibility to SARS-CoV-2</measure>
    <time_frame>baseline</time_frame>
    <description>Possible biomarkers and genetic markers of susceptibility to SARS-CoV-2 using high-performance techniques with serum DNA from the participants</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Lopinavir/ Ritonavir 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hidroxicloroquina 200mg 1 tablet every 12 hours Lopinavir/ Ritonavir 200/50 mg 1 tablet 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imatinib 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hidroxicloroquina 200mg 1 tablet every 12 hours Imatinib 400 mg 1 tablet 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hidroxicloroquina 200mg 1 tablet every 12 hours Baricitinib 4 mg 1 tablet 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hidroxicloroquine</intervention_name>
    <description>Hidroxicloroquine 200 mg BID oral</description>
    <arm_group_label>Baricitinib 4 mg</arm_group_label>
    <arm_group_label>Imatinib 400 mg</arm_group_label>
    <arm_group_label>Lopinavir/ Ritonavir 400 mg</arm_group_label>
    <other_name>Dolquine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir</intervention_name>
    <description>Lopinavir/ritonavir 200/50 mg BID oral</description>
    <arm_group_label>Lopinavir/ Ritonavir 400 mg</arm_group_label>
    <other_name>Best care</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib tablets</intervention_name>
    <description>Imatinib 400 mg QD oral</description>
    <arm_group_label>Imatinib 400 mg</arm_group_label>
    <other_name>Arm A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib Oral Tablet</intervention_name>
    <description>Baricitinib 4 mg QD oral</description>
    <arm_group_label>Baricitinib 4 mg</arm_group_label>
    <other_name>Arm B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form

          -  ≥18 years

          -  Confirmed diagnosis Pneumonia Covid19 positive

          -  ECOG functional state 0 or 1

          -  Less than 7 days from onset of symptoms saw.

          -  NO contraindication for medication

          -  ECG QT &lt;0.4

          -  Adequate liver, kidney and hematological function (or within the safety range to use
             these drugs):

               1. Absolute granulocyte count&gt; 1.5 x 109 / L

               2. Absolute platelet count&gt; 100 x 109 / L

               3. Hb&gt; 10 g / dL

               4. Cr &lt;1.5 mg / dL or Clearance&gt; 50mL / min

               5. Bilirubin &lt;3 ULN 6. AST / ALT ≤ 2.5 times ULN

        Exclusion Criteria:

          -  No Covid confirmation

          -  No pneumonia

          -  Previous treatment with any of the study drugs

          -  Concomitant serious medical condition:

               1. Congestive Heart failure

               2. Acute myocardial infarction 6 months prior

               3. Unstable Angina

               4. Cardiomyopathy

               5. Unstable Ventricular Arrhythmia

               6. Uncontrolled Hypertension

               7. Uncontrolled psychotic disorders

               8. Serious active infections

               9. HIV infections

              10. Active hepatitis

              11. Neoplasia in active cancer treatment

          -  Inability to take oral medication or malabsorption syndrome saw.

          -  Inability to comply with study and follow-up procedures

          -  History of only relevant thromboembolic or hemorrhagic episodes in the last 6 months

          -  Contraindication to any study medication

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Bernal, Ph MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Fuenlabrada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Bernal, Ph MD</last_name>
    <phone>+34916006180</phone>
    <email>david.bernal@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Berta Nasarre, Pharmacist</last_name>
    <phone>+34916006584</phone>
    <email>bnasarre@ext.cnio.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Bernal, Ph MD</last_name>
      <phone>+34916006180</phone>
      <email>david.bernal@salud.madrid.org</email>
    </contact>
    <contact_backup>
      <last_name>Juan Victor San Martin, Ph</last_name>
      <phone>+34916006180</phone>
      <email>juanvictor.san@salud.madrid.org</email>
    </contact_backup>
    <investigator>
      <last_name>David Bernal, Ph MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Victor San Martín, Ph</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diego Malon, Ph</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mario García Gil, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Berta Nasarre López, Pharm</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Belén Hernández Muniesa, Pharm</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alicia Algaba, BS MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando Bermejo, Ph MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Urioste, Ph MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

